News

 

ACT Genomics partners with Quark Biosciences to develop tumor micro-environment chip

ACT Genomics announces partnership with Quark Biosciences to develop tumor micro-environment chip (TME Chip) as a universal biomarker for cancer immunotherapy, aiming to increase the response rate by identifying suitable patients with precision.

Get to know more about ACT Genomics

E-newsletters

2017.Dec.29th

ACT Genomics January E-newsletter

2018 VOL.01

See More

Keep in Touch

Subscribe to ACT Genomics Newsletter to be connected to the latest precision medicine